Anthem Biosciences IPO GMP Today: The Anthem Biosciences IPO has been one of the most talked-about market events this week, with investors eagerly tracking its Grey Market Premium (GMP) for clues about its listing performance. As the shares hit the BSE and NSE today, July 21, 2025, the buzz around this Contract Research, Development, and Manufacturing Organization (CRDMO) is palpable. Let’s dive into the details of the Anthem Biosciences IPO GMP, its significance, and what it means for investors.
Table of Contents
Understanding Anthem Biosciences and Its IPO
Anthem Biosciences, founded in 2006 and headquartered in Bengaluru, is a leading Indian CRDMO. It offers end-to-end services in drug discovery, development, and manufacturing, catering to global clients across 44 countries, including the US, Europe, and Japan. The company specializes in New Chemical Entities (NCEs) and New Biological Entities (NBEs), serving both emerging biotech firms and large pharmaceutical giants. Its IPO, which opened for subscription from July 14 to July 16, 2025, aimed to raise ₹3,395 crore through an Offer for Sale (OFS) of 5.96 crore equity shares. The price band was set at ₹540–₹570 per share, with a minimum lot size of 26 shares, requiring a minimum investment of ₹14,040 for retail investors.
What Is the Grey Market Premium (GMP) Today?
As of July 21, 2025, the GMP for Anthem Biosciences IPO is reported at ₹179, according to sources tracking grey market activities. This suggests that the shares are trading at a premium of ₹179 over the upper price band of ₹570, pointing to an estimated listing price of around ₹749. This translates to an expected listing gain of approximately 31.57%, a figure that has sparked excitement among investors. The GMP has shown volatility, with earlier figures ranging from ₹100 on July 14 to a high of ₹158 on July 17, reflecting growing market enthusiasm. However, GMP is an unregulated indicator, and investors should approach it with caution.
Subscription Status and Market Response
The Anthem Biosciences IPO saw an overwhelming response during its subscription period, closing with an overall subscription of 67.42 times. The retail category was subscribed 5.98 times, while the Qualified Institutional Buyers (QIBs) segment saw an impressive 192.80 times subscription, and Non-Institutional Investors (NIIs) subscribed 44.70 times. This robust demand underscores the market’s confidence in Anthem’s growth potential. The company’s strong financials, with a 30% revenue growth to ₹1,844.6 crore and a net profit of ₹451.3 crore in FY25, further bolstered investor interest. The high subscription rates and rising GMP suggest a favorable listing, but investors should remain mindful of market dynamics.
Financial Strengths and Risks to Consider
Anthem Biosciences stands out for its integrated capabilities in both small and large molecule drugs, a rarity among Indian CRDMOs. Its 36.81% EBITDA margin in FY25 is among the highest in the industry, and its focus on high-margin segments like fee-for-service contracts and specialty ingredients like probiotics and biosimilars adds to its appeal. The company’s revenue has grown at a 25% CAGR from FY20 to FY25, with a 37% CAGR in net profit. However, the IPO’s P/E ratio of 70.9x is on the higher side compared to peers like Divi’s Labs (45–50x) and Syngene (60x), indicating a premium valuation. Since the IPO is entirely an OFS, the company won’t receive any proceeds, which may limit its immediate growth capital. Investors should weigh these factors carefully.
Should You Invest Post-Listing?
With the shares listing today, July 21, 2025, the GMP of ₹179 signals a strong debut, potentially delivering over 30% gains for allottees. Brokerages like Anand Rathi and SBI Securities have recommended subscribing for long-term investment, citing Anthem’s leadership in the CRDMO space and its strong financial track record. However, the high P/E ratio and the unregulated nature of GMP call for caution. For long-term investors, Anthem’s growth in high-demand areas like peptides and fermentation-based products makes it a compelling bet, but short-term traders should monitor market trends closely. Always consult a SEBI-registered financial advisor and review the Red Herring Prospectus (RHP) before making investment decisions.
In conclusion, the Anthem Biosciences IPO GMP today reflects strong market sentiment, but its success on the bourses will depend on broader market conditions and investor confidence. Keep an eye on the listing performance and stay informed!